Market revenue in 2023 | USD 39.8 million |
Market revenue in 2030 | USD 193.5 million |
Growth rate | 25.3% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.08% in 2023. Horizon Databook has segmented the Sweden cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
The pharmaceutical market in Sweden is highly competitive, with multinational pharmaceutical companies and domestic manufacturers operating locally. The market is driven by innovation, with a significant number of clinical trials taking place in Sweden.
The country has a strong R&D infrastructure, with several universities and research institutes collaborating with the pharmaceutical industry to drive innovation & develop new therapies. Overall, the pharmaceutical market offers opportunities for domestic and international companies; however, navigating the complex regulatory landscape is crucial for success.
Furthermore, the increasing demand for cell & gene therapy CDMO services in Sweden can be attributed to the increasing initiatives, such as mergers & acquisitions, partnerships, and investments. For instance, in February 2022, Recipharm, a global CDMO, acquired Vibalogics, a virotherapy CDMO, expanding into oncolytic viruses, viral vaccines, and gene therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Sweden cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account